Identification of CCR2 and CD180 as Robust Pharmacodynamic Tumor and Blood Biomarkers for Clinical Use with BRD4/BET Inhibitors
暂无分享,去创建一个
Greg O'Connor | J Carl Barrett | A. Dulak | J. Barrett | G. O'Connor | P. Petteruti | T. Yeh | Austin Dulak | Huawei Chen | Huawei Chen | Tammie C Yeh | Philip Petteruti | Maureen Hattersley | M. Hattersley
[1] M. Heikenwalder,et al. CCL2-CCR2 Signaling in Disease Pathogenesis. , 2015, Endocrine, metabolic & immune disorders drug targets.
[2] P. Sandy,et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains , 2011, Proceedings of the National Academy of Sciences.
[3] Alan J Tackett,et al. Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma , 2015, Epigenetics.
[4] Qiao Jing Lew,et al. Brd4 and HEXIM1: Multiple Roles in P-TEFb Regulation and Cancer , 2014, BioMed research international.
[5] H. Dombret,et al. Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. , 2016, The Lancet. Haematology.
[6] C. Wells,et al. Age-specific biological and molecular profiling distinguishes paediatric from adult acute myeloid leukaemias , 2018, Nature Communications.
[7] H. Dombret,et al. BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells , 2015, Oncotarget.
[8] J. Zuber,et al. The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML , 2018, Oncogene.
[9] A. Dulak,et al. Potent and selective bivalent inhibitors of BET bromodomains. , 2016, Nature chemical biology.
[10] R. Muschel,et al. Targeting the CCL2-CCR2 signaling axis in cancer metastasis , 2016, Oncotarget.
[11] C. A. Roberts,et al. Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153). , 2016, Journal of medicinal chemistry.
[12] Marie Jung,et al. Targeting BET bromodomains for cancer treatment. , 2015, Epigenomics.
[13] S. Lowe,et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia , 2011, Nature.
[14] David A. Orlando,et al. Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers , 2013, Cell.
[15] J. Greenbaum,et al. Selective inhibition of CD4+ T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitors , 2012, Proceedings of the National Academy of Sciences.
[16] P. Jackson,et al. Development and classes of epigenetic drugs for cancer. , 2014, Biochemical and biophysical research communications.
[17] R. Prinjha,et al. BET bromodomain inhibition suppresses transcriptional responses to cytokine‐Jak‐STAT signaling in a gene‐specific manner in human monocytes , 2015, European journal of immunology.
[18] T. E. Schultz,et al. The RP105/MD‐1 complex: molecular signaling mechanisms and pathophysiological implications , 2017, Journal of leukocyte biology.
[19] G. Mills,et al. AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies , 2016, Molecular Cancer Therapeutics.
[20] G. Shapiro,et al. Abstract CT014: GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of a phase I/II open-label single-agent study in patients with NUT midline carcinoma (NMC) and other cancers , 2016 .
[21] G. Salles,et al. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. , 2016, The Lancet. Haematology.
[22] P. Young,et al. RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease. , 2016, Atherosclerosis.
[23] I. Flinn,et al. BET Inhibitor CPI-0610 Is Well Tolerated and Induces Responses in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma: Preliminary Analysis of an Ongoing Phase 1 Study , 2015 .
[24] J. Qi,et al. HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist , 2015, Leukemia.
[25] L. Ouyang,et al. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery , 2015, Oncotarget.
[26] A. Belkina,et al. BET Protein Function Is Required for Inflammation: Brd2 Genetic Disruption and BET Inhibitor JQ1 Impair Mouse Macrophage Inflammatory Responses , 2013, The Journal of Immunology.
[27] Allen J. Taylor,et al. Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial. , 2011, Journal of the American College of Cardiology.
[28] Y. Ye,et al. Bromodomain and extra-terminal domain bromodomain inhibition prevents synovial inflammation via blocking IκB kinase-dependent NF-κB activation in rheumatoid fibroblast-like synoviocytes. , 2016, Rheumatology.
[29] G. Pelosi,et al. Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628. , 2016, Cancer discovery.